Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

BACKGROUND: Considering cell cycle dependent cytotoxicity, intercalation of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) may be a treatment option in non-small cell lung cancer (NSCLC). This randomized phase 2 study compared the efficacy of paclitaxel and...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yoon Ji, Lee, Dae Ho, Choi, Chang Min, Lee, Jung Shin, Lee, Seung Jin, Ahn, Jin-Hee, Kim, Sang-We
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619194/
https://www.ncbi.nlm.nih.gov/pubmed/26493267
http://dx.doi.org/10.1186/s12885-015-1714-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619194/
https://www.ncbi.nlm.nih.gov/pubmed/26493267
http://dx.doi.org/10.1186/s12885-015-1714-y

Ejemplares similares